Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2023 Earnings Presentation
13 slides from Indivior Pharmaceuticals's earnings presentation, Apr 27, 2023
Slide 1: Q1 2023 Results
Q1 2023 Results April 27, 2023
Slide 2: Important cautionary statement regarding forward-looking statements
Important cautionary statement regarding forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2023 and its medium- and long-term grow
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q1 2023 key messages
Q1 2023 key messages Excellent start to FY 2023: Q1 total NR1 +22% YOY / Reported op. profit +6% and adjusted2 op. ( profit +31% YOY / Strong SUBLOCADE® (+55%) and PERSERIS (+60%) NR growth YOY Opiant Pharmaceuticals acquisition successfully completed and integrated FY 2023 guidance revised to refle
Slide 5: Executing clear strategies for value creation
Executing clear strategies for value creation 1 2 3 4 Grow Build & Optimize SUBLOCADE® Diversify Progress Operating >$1.5bn Revenue Pipeline Model • SUBLOCADE Q1 2023 NR of $132m, +55% • Opiant Pharmaceuticals acquisition • AELIS AEF0117 (CUD4): Phase 2b Last • $803m of gross cash and investments7 •
Slide 6: Opiant update
Opiant update Transaction closed March 2nd; integration completed May 22nd PDUFA for OPNT003 (emergency treatment of known or suspected opioid overdose); anticipated Q4 2023 launch (if approved) Intention to price OPNT003 responsibly considering innovation Targeting "public interest" market with hig
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Q1 2023 financial highlights
Q1 2023 financial highlights Takeaways (vs. Q1 2022) Operating Results – Reported and Adjusted2 ➤ Top-line NR growth of 22% $ mil Q1 23 Q1 22 Change Net Revenue: 253 207 22% ✓ U.S. NR up 27% U.S. 209 165 27% ROW3 44 42 5% ✓ ROW NR up 5% including FX (up 13% Gross Profit: 214 170 26% Adjusted excludi
Slide 9: Cash & borrowing position
Cash & borrowing position Cash & Borrowing Takeaways Total gross cash & investments of 803m1 ➤ Cash and investments primarily held in USD Q1 23 FY 22 ➤ Opiant acquisition completed for $124m (net of ($ in mil.) transferred cash balance) Cash & Cash Equivalents $588 $774 ➤ Completed second $100m shar
Slide 10: FY 2023 guidance updated
FY 2023 guidance updated Guidance includes the impact from the closed transaction with Opiant Additional Top-Line Assumptions Pharmaceuticals and continued SUBOXONE Film resilience in US ➤ Underlying BMAT market growth of mid- to high-single digits FY 2023 Revised Guidance1 ($ in mil.) ➤ OPNT003 NR
Slide 11: Appendix
Appendix 11
Slide 12: Financial Reconciliation: Q1 2023 & Q1 2022
Financial Reconciliation: Q1 2023 & Q1 2022 Q1 2023 Q1 2022 ($ in mil. at Actual FX ) Net Income / (Loss) 44 41 Net interest (expense) / income (1) 6 Taxation 14 7 Operating Profit / (Loss) 57 54 Adjustments 14 N/A Adjusted Operating Profit / (Loss) 71 54 Q1 2023 Notes: $12m exceptional transaction
Slide 13: ANS INDIVIOR
Nz ANS INDIVIOR
Indivior Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix